SEARCH

SEARCH BY CITATION

References

  • 1
    Burke LB. Acceptable evidence for pharmaceutical advertising and labeling. Drug Information Association Workshop, New Orleans, LA.
  • 2
    Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims in labeling and promotion. Value Health 1999; 2: 11327.
  • 3
    Santanello NC, Baker D, Cappelleri JC et al. Regulatory Issues for Health-Related Quality of Life—PhRMA Health Outcomes Committee Workshop, 1999. Value Health 2002; in press.
  • 4
    Engel JF, Blackwell RD, Miniard PW, eds. Consumer Behavior. Fort Worth, Texas: Dryden Press, 1995.
  • 5
    Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven, 1996.
  • 6
    Food and Drug Administration. Guidance for Industry; Content and Format of the Adverse Reactions Section of Labeling for Human Prescription Drugs and Biologics, May 2000. Available at www.fda.gov/cder/guidance/1888dft.htm. Accessed October 30, 2000.
  • 7
    Food and Drug Administration. Guidance for Industry; Providing Clinical Evidence of Effectiveness for Human Prescription Drugs and Biologics, May 1998 Available at www.fda.gov/cder/guidance/1397fnl.pdf. Accessed October 30, 2000.
  • 8
    Food and Drug Administration. Requirements for the content and format of labeling for human prescription drugs and biologics. Requirements for prescription drug product labels; proposed rule. Federal Register 2000; 65: 81082131.
  • 9
    Food and Drug Administration. Draft Guidance for Industry; Clinical Studies Section of Labeling for Prescription Drugs and Biologics—Content and Format, July 2001. Available at www.fda.gov/ cder/guidance/ 1890dft.htm. Accessed August 29, 2001.
  • 10
    Food and Drug Administration. Warning Letters and Untitled Letters to Pharmaceutical Companies, 2000. Available at www.fda.gov/cder/ warn/ warn2000.htm. Accessed October 30, 2000 and August 13, 2001.
  • 11
    Morris LA, Miller D. Regulating functional claims in advertising. Drug Information Association Workshop, New Orleans, LA, October, 2000.
  • 12
    Peter JP, Olsen JC. Consumer Behavior and Marketing Strategy (4th ed.). Boston: Irwin Press, 1996.
  • 13
    Mauskopf JA, Austin MA, Dix LP, Berzon RA. Estimating the value of a generic quality-of-life measure. Med Care 1995; 33: AS195AS202.
  • 14
    Solomon GD, Skobjeranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the medical outcomes study instrument. Headache 1994; 34: 1437.
  • 15
    Wu AW, Lamping DL. Assessment of quality of life in HIV disease. AIDS 1994; 8(Suppl. 1): 534959.
  • 16
    Federal Trade Commission. Policy statement regarding advertising substantiation program. Federal Register 1984; 49: 309991001.
  • 17
    Conference Committee Report, Food and Drug Modernization Act. Available from ISPOR US Legislation Briefing, Background Information. Washington, DC. January, 1998.
  • 18
    Neumann PJ, Zinner DE, Paltiel AD. The FDA's regulation of cost-effectiveness claims. Health Aff 1996; 15: 5471.
  • 19
    Calfee J, Papplardo J. Public policy issues in health claims for food. J Public Policy Marketing 1991; 6: 6583.
  • 20
    Jack W. Pharmaceutical differentiation through quality of life measurement: a case study. J Pharmaceut Marketing Meas 1991; 6: 6583.
  • 21
    Santanello NC, Baker D, Cappelleri JC Regulatory issues for health-related quality of life—PhRMA Health Outcomes Committee Workshop, 1999, Value Health 2002; In press.